The Experts below are selected from a list of 47487 Experts worldwide ranked by ideXlab platform
Akihiko Kondo - One of the best experts on this subject based on the ideXlab platform.
-
glutathione production from mannan based Bioresource by mannanase mannosidase expressing saccharomyces cerevisiae
Bioresource Technology, 2017Co-Authors: Alex Prima, Kiyotaka Y. Hara, Apridah Cameliawati Djohan, Norimasa Kashiwagi, Prihardi Kahar, Jun Ishii, Hideki Nakayama, Fumiyoshi Okazaki, Bambang Prasetya, Akihiko KondoAbstract:This work aims to produce glutathione directly from mannan-based Bioresources using engineered Saccharomyces cerevisiae. Mannan proved to be a valuable carbon source for glutathione production by this organism. Mannan-hydrolyzing S. cerevisiae was developed by heterologous expression of mannanase/mannosidase on its cell surface. This strain efficiently produced glutathione from mannose polysaccharide, β-1,4-mannan. Furthermore, it produced glutathione from locust bean gum (LBG), a highly dense and inexpensive mannan-based Bioresource, as sole carbon source. Glutathione productivity from LBG was enhanced by engineering the glutathione metabolism of mannan-hydrolyzing S. cerevisiae. Expression of extracellular mannanase/mannosidase protein combined with intracellular metabolic engineering is potentially applicable to the efficient, environmentally friendly bioproduction of targeted products from mannan-based Bioresources.
-
Glutathione Production From Mannan-Based Bioresource by mannanase/mannosidase Expressing Saccharomyces Cerevisiae
Bioresource technology, 2017Co-Authors: Alex Prima, Kiyotaka Y. Hara, Apridah Cameliawati Djohan, Norimasa Kashiwagi, Prihardi Kahar, Jun Ishii, Hideki Nakayama, Fumiyoshi Okazaki, Bambang Prasetya, Akihiko KondoAbstract:This work aims to produce glutathione directly from mannan-based Bioresources using engineered Saccharomyces cerevisiae. Mannan proved to be a valuable carbon source for glutathione production by this organism. Mannan-hydrolyzing S. cerevisiae was developed by heterologous expression of mannanase/mannosidase on its cell surface. This strain efficiently produced glutathione from mannose polysaccharide, β-1,4-mannan. Furthermore, it produced glutathione from locust bean gum (LBG), a highly dense and inexpensive mannan-based Bioresource, as sole carbon source. Glutathione productivity from LBG was enhanced by engineering the glutathione metabolism of mannan-hydrolyzing S. cerevisiae. Expression of extracellular mannanase/mannosidase protein combined with intracellular metabolic engineering is potentially applicable to the efficient, environmentally friendly bioproduction of targeted products from mannan-based Bioresources.
Miles Parkes - One of the best experts on this subject based on the ideXlab platform.
-
ibd Bioresource an open access platform of 25 000 patients to accelerate research in crohn s and colitis
Gut, 2019Co-Authors: Miles ParkesAbstract:Give us the tools and we will finish the job -Winston Churchill An alliance of clinicians, academics, research nurses, funders, coordinators, programmers and, most importantly, patients has come together in the UK to deliver a powerful new platform to accelerate Crohn’s and Colitis research—the inflammatory bowel disease (IBD) Bioresource. As part of the National Institute for Health Research (NIHR) Bioresource for translational research, 25 000 patients in over 90 hospitals UK-wide have signed up since we launched in January 2016 (figure 1). All have detailed phenotypes databased including Montreal classification,1 treatment response history (updated annually), surgical history and comorbidities (see IBD Bioresource panel descriptive, Clinical data collection sheet and Health and Lifestyle questionnaire). Serum, plasma and DNA samples are banked; and genome-wide genetic profiling undertaken. Participants’ data and samples can be studied, and they themselves surveyed or recalled for resampling or downstream studies (see figure 2). Critically, such studies can be led by any UK or overseas investigator whether from the worlds of clinical research, pharmacovigilance, science or industry. Figure 1 IBD Bioresource recruitment in over 90 hospitals in the UK. IBD, inflammatory bowel disease. Figure 2 How the IBD Bioresource works. HES, Hospital Episode Statistics; HSCN, Health Social Care Network; IBD, inflammatory bowel disease; NHS, National Health Service. A key motivation is to leverage recent genetics advances, and by understanding the functional impact of IBD-associated gene variants accelerate translation of the new knowledge for clinical benefit. Beyond this, it is increasingly evident that the IBD Bioresource can facilitate a wide spectrum of research. This might include anything from mining existing data or samples or surveying the cohort regarding outcomes of newly licensed treatments, to pharmacogenetic research. It could also be used to expedite recruitment to intervention studies, including experimental medicine and conventional drug trials. Gene discovery in Crohn’s disease and ulcerative colitis has placed …
-
IBD Bioresource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
Gut, 2019Co-Authors: Miles ParkesAbstract:Give us the tools and we will finish the job -Winston Churchill An alliance of clinicians, academics, research nurses, funders, coordinators, programmers and, most importantly, patients has come together in the UK to deliver a powerful new platform to accelerate Crohn’s and Colitis research—the inflammatory bowel disease (IBD) Bioresource. As part of the National Institute for Health Research (NIHR) Bioresource for translational research, 25 000 patients in over 90 hospitals UK-wide have signed up since we launched in January 2016 (figure 1). All have detailed phenotypes databased including Montreal classification,1 treatment response history (updated annually), surgical history and comorbidities (see IBD Bioresource panel descriptive, Clinical data collection sheet and Health and Lifestyle questionnaire). Serum, plasma and DNA samples are banked; and genome-wide genetic profiling undertaken. Participants’ data and samples can be studied, and they themselves surveyed or recalled for resampling or downstream studies (see figure 2). Critically, such studies can be led by any UK or overseas investigator whether from the worlds of clinical research, pharmacovigilance, science or industry. Figure 1 IBD Bioresource recruitment in over 90 hospitals in the UK. IBD, inflammatory bowel disease. Figure 2 How the IBD Bioresource works. HES, Hospital Episode Statistics; HSCN, Health Social Care Network; IBD, inflammatory bowel disease; NHS, National Health Service. A key motivation is to leverage recent genetics advances, and by understanding the functional impact of IBD-associated gene variants accelerate translation of the new knowledge for clinical benefit. Beyond this, it is increasingly evident that the IBD Bioresource can facilitate a wide spectrum of research. This might include anything from mining existing data or samples or surveying the cohort regarding outcomes of newly licensed treatments, to pharmacogenetic research. It could also be used to expedite recruitment to intervention studies, including experimental medicine and conventional drug trials. Gene discovery in Crohn’s disease and ulcerative colitis has placed …
-
pth 094 thiopurine adverse events in patients with inflammatory bowel disease in the uk ibd Bioresource cohort
Gut, 2019Co-Authors: You Yi Hong, Rasha Shawky, Achini Diana Withanachchi, Miles ParkesAbstract:Introduction The Inflammatory Bowel Disease (IBD) Bioresource is recruiting patients with Crohn’s Disease (CD), Ulcerative Colitis (UC) or IBD type Unclassified (IBDU) from 89 hospitals UK-wide. >19,000 subjects have been recruited to date. Data have been collected on disease phenotype, treatment, adverse events and treatment response. Aim To describe the prevalence of adverse events related to thiopurine exposure among the IBD Bioresource cohort Methods A descriptive, retrospective analysis of the IBD Bioresource database has been performed to determine the incidence of short and long-term adverse events related to the use of thiopurines in the treatment of inflammatory bowel disease. All patients who have had exposure to thiopurine therapy (azathioprine or 6-mercaptopurine) were included. Results 10 092 (57.8%) patients within the IBD Bioresource cohort have had some exposure to thiopurine therapy during their disease course, either as monotherapy or in combination with anti-TNF. 9480 patients (94.0%) have been treated with azathioprine (AZA) and 2335 patients (23.1%) have been treated with 6-mercaptopurine (6 MP). Of the 9480 patients who have been treated with azathioprine, 4167 patients (44.0%) remain on this therapy. 2369 patients (24.9%) ceased azathioprine due to adverse events. 1723 of the 2335 (73.8%) patients treated with 6 MP had previously been treated with AZA and been intolerant. 684 patients (29.3%) ceased 6 MP due to adverse events. The most commonly reported adverse events were nausea and vomiting (9.6%), followed by deranged liver function tests (5.1%), non-specified patient intolerance (2.4%), flu like symptoms (2.3%) and abdominal pain (2.3%). The incidence of clinically serious side effects was low. Pancreatitis was reported in 2.2% of patients; and leukopenia (total WCC Conclusion We report a large, real world series of patients with IBD treated with azathioprine or 6 MP. Thiopurines were ceased due to side effects in 25.1% of patients overall. The incidence of adverse events with 6 MP was only modestly higher than in those treated with azathioprine, despite 73.8% having been previously treated with azathioprine. Serious clinical adverse events related to thiopurine exposure were observed but at low frequency.
-
PTH-093 Efficacy of thiopurine monotherapy in the UK inflammatory bowel disease Bioresource cohort
Posters, 2019Co-Authors: You Yi Hong, Laetitia C. Pele, Rachel Simpkins, Catherine Thorbinson, Deepthy Francis, Rasha Shawky, Miles ParkesAbstract:Introduction IBD Bioresource is currently recruiting patients with Crohn’s Disease (CD), Ulcerative Colitis (UC) and IBDU from 89 hospitals UK-wide. To date >19,000 patients have been recruited with detailed clinical phenotype data plus serum and DNA, and all will have had Genome-Wide Association Scans ± whole genome sequencing by April 2019. Subjects can be recalled by genotype or phenotype for downstream studies by any investigator. Thiopurines play a key role in the management of IBD - used either as monotherapy or in combination with other treatments to maintain remission. However, data regarding long term effectiveness are sparse. Aims To characterise the long term effectiveness of thiopurine monotherapy among subjects in the IBD Bioresource cohort Method IBD phenotype data were extracted by research nurses and clinicians in each hospital site following case note review and uploaded to a Redcap database. Response to treatment was empirically classified as ‘effective’, ‘not effective’, and 5 other categories (‘transient’, ‘partial’, ‘intolerant’ etc.). By interrogating the Redcap database and analysing the data in R we sought to identify the proportion of patients in whom thiopurine was effective as monotherapy – in whom (1) treatment was classified as ‘effective’ and (2) there had been no escalation to biologic therapy or need for surgery for the duration of thiopurine therapy. Patients started on anti TNF therapy at thiopurine initiation or undergoing surgery in the 1 year prior to initiation were excluded since we could not assess effectiveness of thiopurine monotherapy in these groups. Results Data were available on 8296 IBD Bioresource subjects (48.3% male) treated with a thiopurine and meeting inclusion criteria for assessment. In 2417 patients (29.1%) thiopurine monotherapy had been deemed to be an effective maintenance treatment - meeting both criteria (1) and (2) above. Long term effectiveness was higher in UC/IBDU (1531/3485; 43.9%) compared to CD (883/4799; 18.4% - Chi Sq P Conclusion Thiopurines can be effective in producing durable remission, particularly in UC. Pharmacogenetic studies will follow. The IBD Bioresource is open to all investigators for recall of well characterised patient cohorts.
-
PWE-044 The IBD Bioresource: progressing from genetics to function and clinical translation in CD & UC
IBD, 2018Co-Authors: Laetitia C. Pele, Rachel Simpkins, Catherine Thorbinson, Deepthy Francis, Sophie Lewis, Rasha Shawky, Miles ParkesAbstract:Introduction He Inflammatory Bowel Disease (IBD) Bioresource was established by the UK IBD Genetics Consortium and the NIHR Bioresource in 2016 to expedite functional characterisation of IBD-associated variants and clinical translation of recent genetics advances. It aims to recruit 25,000 patients, across hospitals sites nationwide, who can then be further invited for future research studies based on genotype and/or phenotype. Methods The Main cohort comprises individuals with established Crohn’s Disease (CD) and Ulcerative Colitis (UC). Both clinical and self-reported phenotype data are collected, alongside plasma, serum and DNA samples for Whole Genome Sequencing. The Inception cohort aims to recruit a sub-set of 1,000 individuals newly diagnosed with IBD that will provide more detailed sampling, unconfounded by drug treatment or effects of surgery and includes stool, biopsy tissue and whole blood for RNA. This cohort offers a unique resource to undertake omics studies and facilitate research into determinants, predictors and biomarkers of IBD disease course and treatment response. The IBD Bioresource panel can be accessed by any investigators with ethically approved proposals and may involve a range of possible options, such as access to data/samples or recall of genotype-selected participants to donate further samples or trial novel therapies. Results Main cohort Recruitment is still going strong and we now have over 20,000 patients enrolled into our IBD Bioresource panel. Inception cohort This has now been up and running fully since March 2018. We have >40 hospital sites trained to identify and recruit to this cohort. Recruitment is going well too, with 10% of our target reached so far. Translation One measure of success for IBD Bioresource is the use of its panel for the facilitation of IBD research. To date 12 ‘Stage 2 studies’ have applied to utilise the IBD Bioresource. Of the 12 applications, ∼40% requested access to anonymised samples and data while the remaining ∼60% required involvement of participants (recall to sites/completion of online questionnaires). Field of studies ranged from disease mechanistic, immunology through to genetic, environmental and microbial interactions. We aim to give further update about the current state of the project, which will be over 3 years. This will include key achievements and milestones reached, the ‘highs and lows’ of setting up large cohort of patients and highlights on selected stage 2 studies. Conclusion The IBD Bioresource and its network are on course to fulfil their goals.
Anne Cambon-thomsen - One of the best experts on this subject based on the ideXlab platform.
-
Favouring the sharing of samples and data in research. Crediting and Rewarding
2019Co-Authors: Mogens Thomsen, Laurence Mabile, Anne Cambon-thomsen, Romain David, Sharc RdaAbstract:The immunogenetics community is characterised by a widespread international collaboration between laboratories with exchange of biological samples and data. However, the researchers who are involved in building and curating Bioresources do not always get the credit they deserve and this is an obstacle for sharing practices. Several international initiatives have been taken in order to promote sharing of samples and data. BRIF (Bioresource Research Impact Factor) was initiated in 2003 and intended to develop a framework to enable crediting Bioresources that were uniquely and persistently identified. The way of citing Bioresources was standardised according to a guideline called CoBRA (Citation of Bioresources in journal Articles), published in 2015. This guideline was recommended by the Equator network as well as by other organisations such as GA4GH (Global Alliance for Genomics and Health) and BBMRIERIC, the European infrastructure consortium of biobanking and biomolecular resources. In collaboration with Ubiquity press, the Open Journal of Bioresources (OJB) was created. It is a peer-reviewed open access journal with short papers describing Bioresources dedicated to human biomedical research, providing them with a citable reference. However, as the problem of sharing data and resources and the recognition of such activities in research goes beyond biomedical research, we joined the Research Data Alliance (RDA), creating an interest group called ShaRC (Sharing Rewards and Credits) in 2017. This interest group works with use cases from different research areas. The ongoing work concerns operationalisation and evaluation of the sharing activity complying with the so-called FAIR principles, which mean Findable, Accessible, Interoperable and Reusable. The amount of data published in research in all areas is becoming bigger and bigger and it is important that all sorts of data can be reanalysed and possibly be co-analysed with other data by researchers that are not necessarily those who produced the original data. A grid of evaluation is being built by the ShaRC IG and will benefit from inputs at the next RDA meeting in Philadelphia (April 2019). Some of the results could be of particular interest for the Immunogenetics community and the grid will be updated to be presented at EFI.
-
How to responsibly acknowledge research work in the era of big data and biobanks: ethical aspects of the Bioresource Research Impact Factor (BRIF).
Journal of community genetics, 2017Co-Authors: Heidi Carmen Howard, Laurence Mabile, Deborah Mascalzoni, Gry Houeland, Emmanuelle Rial-sebbag, Anne Cambon-thomsenAbstract:Currently, a great deal of biomedical research in fields such as epidemiology, clinical trials and genetics is reliant on vast amounts of biological and phenotypic information collected and assembled in biobanks. While many resources are being invested to ensure that comprehensive and well-organised biobanks are able to provide increased access to, and sharing of biomedical samples and information, many barriers and challenges remain to such responsible and extensive sharing. Germane to the discussion herein is the barrier to collecting and sharing Bioresources related to the lack of proper recognition of researchers and clinicians who developed the Bioresource. Indeed, the efforts and resources invested to set up and sustain a Bioresource can be enormous and such work should be easily traced and properly recognised. However, there is currently no such system that systematically and accurately traces and attributes recognition to those doing this work or the Bioresource institution itself. As a beginning of a solution to the “recognition problem”, the Bioresource Research Impact Factor/Framework (BRIF) initiative was proposed almost a decade and a half ago and is currently under further development. With the ultimate aim of increasing awareness and understanding of the BRIF, in this article, we contribute the following: (1) a review of the objectives and functions of the BRIF including the description of two tools that will help in the deployment of the BRIF, the CoBRA (Citation of Bioresources in journal Articles) guideline, and the Open Journal of Bioresources (OJB); (2) the results of a small empirical study on stakeholder awareness of the BRIF and (3) a brief analysis of the ethical dimensions of the BRIF which allow it to be a positive contribution to responsible biobanking.
-
Title: How to responsibly acknowledge research work in the era of big data and biobanks: Ethical aspects of the Bioresource Research Impact Factor (BRIF)
Journal of Community Genetics, 2017Co-Authors: Heidi Howard, Laurence Mabile, Deborah Mascalzoni, Gry Houeland, Emmanuelle Rial-sebbag, Anne Cambon-thomsenAbstract:Currently, a great deal of biomedical research in fields such as epidemiology, clinical trials and genetics is reliant on vast amounts of biological and phenotypic information collected and assembled in biobanks. While many resources are being invested to ensure that comprehensive and well-organised biobanks are able to provide increased access to, and sharing of biomedical samples and information, many barriers and challenges remain to such responsible and extensive sharing. Germane to the discussion herein is the barrier to collecting and sharing Bioresources related to the lack of proper recognition of researchers and clinicians who developed the Bioresource. Indeed, the efforts and resources invested to set up and sustain a Bioresource can be enormous and such work should be easily traced and properly recognised. However, there is currently no such system that systematically and accurately traces and attributes recognition to those doing this work or the Bioresource institution itself. As a beginning of a solution to the "recognition problem", the Bioresource Research Impact Factor/Framework (BRIF) initiative was proposed almost a decade and a half ago and is currently under further development. With the ultimate aim of increasing awareness and understanding of the BRIF, in this article, we contribute the following: (1) a review of the objectives and functions of the BRIF including the description of two tools that will help in the deployment of the BRIF, the CoBRA (Citation of Bioresources in journal Articles) guideline, and the Open Journal of Bioresources (OJB); (2) the results of a small empirical study on stakeholder awareness of the BRIF and (3) a brief analysis of the ethical dimensions of the BRIF which allow it to be a positive contribution to responsible biobanking.
-
Biobankers: Treat the Poison of Invisibility with CoBRA, a Systematic Way of Citing Bioresources in Journal Articles
Biopreservation and Biobanking, 2016Co-Authors: Federica Napolitani, Alessia Calzolari, Paola De Castro, Laurence Mabile, Anna Maria Rossi, Anne Cambon-thomsen, Elena BravoAbstract:Even though an increasing portion of biomedical research today relies on the use of Bioresources, at present biobankers are not able to trace this use in scientific literature and measure its impact with a variety of citation metrics. The "BRIF (Bioresource Research Impact Factor) and journal editors" subgroup was created precisely with the aim to study this issue and to build a standardized system to cite Bioresources in journal articles. This report aims at presenting a guideline for Citation of Bioresources in journal Articles (CoBRA). The guideline offers for the first time a standard for citing Bioresources (including biobanks) within journal articles. It will increase their visibility and promote their sharing.
-
ELPUB - Towards New Metrics For Bioresource Use
2016Co-Authors: Laurence Mabile, Elena Bravo, Paola De Castro, Barbara Parodi, Mogens Thomsen, Samuel Moore, Anne Cambon-thomsenAbstract:The BRIF is an ongoing initiative that encompasses reflections and actions from various stakeholders (researchers, funders, industrials, editors) towards i/ standardised identification schemes and reporting for better visibility and tracing of Bioresources on the web; ii/ incentive policies from hosting institutions; iii/ creation of tools allowing follow up of their use. Tracing the use of Bioresource is the first step in this process and for this purpose we have published the CoBRA (Citation of Bioresources in journal Articles) guideline, launched the Open Journal of Bioresources and started developing new metrics. The CoBRA guideline aims to standardise the citation of Bioresources in scientific articles in order to trace their use on the web. The Open Journal of Bioresources (OJB) was created in close collaboration with the open access publisher Ubiquity Press allowing both the resources and the OJB papers to be cited, and also providing authors with tools to get metrics on reuse and impact. New better adapted metrics are being worked out in a dedicated BRIF working subgroup. A first list of relevant parameters to take into account in the impact measure of Bioresources has been provided. The tools proposed here foster easier access to samples and associated data as well as their optimised use, sharing and recognition for data producers. Input from the scientific editorial community would be highly appreciated at this stage.
Alex Prima - One of the best experts on this subject based on the ideXlab platform.
-
glutathione production from mannan based Bioresource by mannanase mannosidase expressing saccharomyces cerevisiae
Bioresource Technology, 2017Co-Authors: Alex Prima, Kiyotaka Y. Hara, Apridah Cameliawati Djohan, Norimasa Kashiwagi, Prihardi Kahar, Jun Ishii, Hideki Nakayama, Fumiyoshi Okazaki, Bambang Prasetya, Akihiko KondoAbstract:This work aims to produce glutathione directly from mannan-based Bioresources using engineered Saccharomyces cerevisiae. Mannan proved to be a valuable carbon source for glutathione production by this organism. Mannan-hydrolyzing S. cerevisiae was developed by heterologous expression of mannanase/mannosidase on its cell surface. This strain efficiently produced glutathione from mannose polysaccharide, β-1,4-mannan. Furthermore, it produced glutathione from locust bean gum (LBG), a highly dense and inexpensive mannan-based Bioresource, as sole carbon source. Glutathione productivity from LBG was enhanced by engineering the glutathione metabolism of mannan-hydrolyzing S. cerevisiae. Expression of extracellular mannanase/mannosidase protein combined with intracellular metabolic engineering is potentially applicable to the efficient, environmentally friendly bioproduction of targeted products from mannan-based Bioresources.
-
Glutathione Production From Mannan-Based Bioresource by mannanase/mannosidase Expressing Saccharomyces Cerevisiae
Bioresource technology, 2017Co-Authors: Alex Prima, Kiyotaka Y. Hara, Apridah Cameliawati Djohan, Norimasa Kashiwagi, Prihardi Kahar, Jun Ishii, Hideki Nakayama, Fumiyoshi Okazaki, Bambang Prasetya, Akihiko KondoAbstract:This work aims to produce glutathione directly from mannan-based Bioresources using engineered Saccharomyces cerevisiae. Mannan proved to be a valuable carbon source for glutathione production by this organism. Mannan-hydrolyzing S. cerevisiae was developed by heterologous expression of mannanase/mannosidase on its cell surface. This strain efficiently produced glutathione from mannose polysaccharide, β-1,4-mannan. Furthermore, it produced glutathione from locust bean gum (LBG), a highly dense and inexpensive mannan-based Bioresource, as sole carbon source. Glutathione productivity from LBG was enhanced by engineering the glutathione metabolism of mannan-hydrolyzing S. cerevisiae. Expression of extracellular mannanase/mannosidase protein combined with intracellular metabolic engineering is potentially applicable to the efficient, environmentally friendly bioproduction of targeted products from mannan-based Bioresources.
Laurence Mabile - One of the best experts on this subject based on the ideXlab platform.
-
Favouring the sharing of samples and data in research. Crediting and Rewarding
2019Co-Authors: Mogens Thomsen, Laurence Mabile, Anne Cambon-thomsen, Romain David, Sharc RdaAbstract:The immunogenetics community is characterised by a widespread international collaboration between laboratories with exchange of biological samples and data. However, the researchers who are involved in building and curating Bioresources do not always get the credit they deserve and this is an obstacle for sharing practices. Several international initiatives have been taken in order to promote sharing of samples and data. BRIF (Bioresource Research Impact Factor) was initiated in 2003 and intended to develop a framework to enable crediting Bioresources that were uniquely and persistently identified. The way of citing Bioresources was standardised according to a guideline called CoBRA (Citation of Bioresources in journal Articles), published in 2015. This guideline was recommended by the Equator network as well as by other organisations such as GA4GH (Global Alliance for Genomics and Health) and BBMRIERIC, the European infrastructure consortium of biobanking and biomolecular resources. In collaboration with Ubiquity press, the Open Journal of Bioresources (OJB) was created. It is a peer-reviewed open access journal with short papers describing Bioresources dedicated to human biomedical research, providing them with a citable reference. However, as the problem of sharing data and resources and the recognition of such activities in research goes beyond biomedical research, we joined the Research Data Alliance (RDA), creating an interest group called ShaRC (Sharing Rewards and Credits) in 2017. This interest group works with use cases from different research areas. The ongoing work concerns operationalisation and evaluation of the sharing activity complying with the so-called FAIR principles, which mean Findable, Accessible, Interoperable and Reusable. The amount of data published in research in all areas is becoming bigger and bigger and it is important that all sorts of data can be reanalysed and possibly be co-analysed with other data by researchers that are not necessarily those who produced the original data. A grid of evaluation is being built by the ShaRC IG and will benefit from inputs at the next RDA meeting in Philadelphia (April 2019). Some of the results could be of particular interest for the Immunogenetics community and the grid will be updated to be presented at EFI.
-
How to responsibly acknowledge research work in the era of big data and biobanks: ethical aspects of the Bioresource Research Impact Factor (BRIF).
Journal of community genetics, 2017Co-Authors: Heidi Carmen Howard, Laurence Mabile, Deborah Mascalzoni, Gry Houeland, Emmanuelle Rial-sebbag, Anne Cambon-thomsenAbstract:Currently, a great deal of biomedical research in fields such as epidemiology, clinical trials and genetics is reliant on vast amounts of biological and phenotypic information collected and assembled in biobanks. While many resources are being invested to ensure that comprehensive and well-organised biobanks are able to provide increased access to, and sharing of biomedical samples and information, many barriers and challenges remain to such responsible and extensive sharing. Germane to the discussion herein is the barrier to collecting and sharing Bioresources related to the lack of proper recognition of researchers and clinicians who developed the Bioresource. Indeed, the efforts and resources invested to set up and sustain a Bioresource can be enormous and such work should be easily traced and properly recognised. However, there is currently no such system that systematically and accurately traces and attributes recognition to those doing this work or the Bioresource institution itself. As a beginning of a solution to the “recognition problem”, the Bioresource Research Impact Factor/Framework (BRIF) initiative was proposed almost a decade and a half ago and is currently under further development. With the ultimate aim of increasing awareness and understanding of the BRIF, in this article, we contribute the following: (1) a review of the objectives and functions of the BRIF including the description of two tools that will help in the deployment of the BRIF, the CoBRA (Citation of Bioresources in journal Articles) guideline, and the Open Journal of Bioresources (OJB); (2) the results of a small empirical study on stakeholder awareness of the BRIF and (3) a brief analysis of the ethical dimensions of the BRIF which allow it to be a positive contribution to responsible biobanking.
-
Title: How to responsibly acknowledge research work in the era of big data and biobanks: Ethical aspects of the Bioresource Research Impact Factor (BRIF)
Journal of Community Genetics, 2017Co-Authors: Heidi Howard, Laurence Mabile, Deborah Mascalzoni, Gry Houeland, Emmanuelle Rial-sebbag, Anne Cambon-thomsenAbstract:Currently, a great deal of biomedical research in fields such as epidemiology, clinical trials and genetics is reliant on vast amounts of biological and phenotypic information collected and assembled in biobanks. While many resources are being invested to ensure that comprehensive and well-organised biobanks are able to provide increased access to, and sharing of biomedical samples and information, many barriers and challenges remain to such responsible and extensive sharing. Germane to the discussion herein is the barrier to collecting and sharing Bioresources related to the lack of proper recognition of researchers and clinicians who developed the Bioresource. Indeed, the efforts and resources invested to set up and sustain a Bioresource can be enormous and such work should be easily traced and properly recognised. However, there is currently no such system that systematically and accurately traces and attributes recognition to those doing this work or the Bioresource institution itself. As a beginning of a solution to the "recognition problem", the Bioresource Research Impact Factor/Framework (BRIF) initiative was proposed almost a decade and a half ago and is currently under further development. With the ultimate aim of increasing awareness and understanding of the BRIF, in this article, we contribute the following: (1) a review of the objectives and functions of the BRIF including the description of two tools that will help in the deployment of the BRIF, the CoBRA (Citation of Bioresources in journal Articles) guideline, and the Open Journal of Bioresources (OJB); (2) the results of a small empirical study on stakeholder awareness of the BRIF and (3) a brief analysis of the ethical dimensions of the BRIF which allow it to be a positive contribution to responsible biobanking.
-
Biobankers: Treat the Poison of Invisibility with CoBRA, a Systematic Way of Citing Bioresources in Journal Articles
Biopreservation and Biobanking, 2016Co-Authors: Federica Napolitani, Alessia Calzolari, Paola De Castro, Laurence Mabile, Anna Maria Rossi, Anne Cambon-thomsen, Elena BravoAbstract:Even though an increasing portion of biomedical research today relies on the use of Bioresources, at present biobankers are not able to trace this use in scientific literature and measure its impact with a variety of citation metrics. The "BRIF (Bioresource Research Impact Factor) and journal editors" subgroup was created precisely with the aim to study this issue and to build a standardized system to cite Bioresources in journal articles. This report aims at presenting a guideline for Citation of Bioresources in journal Articles (CoBRA). The guideline offers for the first time a standard for citing Bioresources (including biobanks) within journal articles. It will increase their visibility and promote their sharing.
-
ELPUB - Towards New Metrics For Bioresource Use
2016Co-Authors: Laurence Mabile, Elena Bravo, Paola De Castro, Barbara Parodi, Mogens Thomsen, Samuel Moore, Anne Cambon-thomsenAbstract:The BRIF is an ongoing initiative that encompasses reflections and actions from various stakeholders (researchers, funders, industrials, editors) towards i/ standardised identification schemes and reporting for better visibility and tracing of Bioresources on the web; ii/ incentive policies from hosting institutions; iii/ creation of tools allowing follow up of their use. Tracing the use of Bioresource is the first step in this process and for this purpose we have published the CoBRA (Citation of Bioresources in journal Articles) guideline, launched the Open Journal of Bioresources and started developing new metrics. The CoBRA guideline aims to standardise the citation of Bioresources in scientific articles in order to trace their use on the web. The Open Journal of Bioresources (OJB) was created in close collaboration with the open access publisher Ubiquity Press allowing both the resources and the OJB papers to be cited, and also providing authors with tools to get metrics on reuse and impact. New better adapted metrics are being worked out in a dedicated BRIF working subgroup. A first list of relevant parameters to take into account in the impact measure of Bioresources has been provided. The tools proposed here foster easier access to samples and associated data as well as their optimised use, sharing and recognition for data producers. Input from the scientific editorial community would be highly appreciated at this stage.